SCHEMBL25291287

SCHEMBL25291287

COC(=O)/C=C/c1ccc2cnn(C3CCCCO3)c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXRA P19793 1/20 0.46
▸ RXRB P28702 1/20 0.46
▸ RXRG P48443 1/20 0.46
▸ KDM4E B2RXH2 4/20 0.42
▸ ALDH1A1 P00352 4/20 0.42
▸ TTR P02766 1/20 0.41
▸ APP P05067 1/20 0.41
▸ NR1H4 Q96RI1 3/20 0.40
▸ PTPN1 P18031 1/20 0.39
▸ EPHX2 P34913 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ JAK2 O60674 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ MGLL Q99685 1/20 0.38
▸ CYP4F2 P78329 1/20 0.38
▸ CYP4A11 Q02928 1/20 0.38
▸ CA12 O43570 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25247427 1.00 RXRA (0.46) RXRARXRBRXRGKDM4EALDH1A1
SCHEMBL29410331 1.00 RXRA (0.46) RXRARXRBRXRGKDM4EALDH1A1
SCHEMBL30327596 0.88 RXRA (0.51) RXRARXRBRXRGKDM4EALDH1A1
SCHEMBL25247927 0.88 RXRA (0.51) RXRARXRBRXRGKDM4EALDH1A1
SCHEMBL30327631 0.87 RXRA (0.48) RXRARXRBRXRGKDM4EALDH1A1
SCHEMBL14827612 0.82 RXRA (0.52) RXRARXRBRXRGKDM4EALDH1A1
SCHEMBL30599506 0.82 ALDH1A1 (0.41) KDM4EALDH1A1TTRAPPNR1H4
SCHEMBL25256819 0.81 ACKR3 (0.42) RXRARXRBRXRGKDM4EALDH1A1
SCHEMBL31261983 0.81 KDM4E (0.43) RXRARXRBRXRGKDM4EALDH1A1
SCHEMBL18399275 0.81 RXRA (0.48) RXRARXRBRXRGALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12497359-B2 Acrylamide derivatives NRG THERAPEUTICS LTD (GB) 2025-12-16 — — US disclosed
EP-4208448-B1 ACRYLAMIDE DERIVATIVES NRG THERAPEUTICS LTD (GB) 2025-04-23 — — EP disclosed
US-20230312466-A1 NOVEL COMPOUNDS NRG THERAPEUTICS LTD (GB) 2023-10-05 — — US disclosed
US-20230312466-A1 NOVEL COMPOUNDS NRG THERAPEUTICS LTD (GB) 2023-10-05 — — US disclosed
US-20230312466-A1 NOVEL COMPOUNDS NRG THERAPEUTICS LTD (GB) 2023-10-05 — — US disclosed
EP-4208448-A1 NOVEL COMPOUNDS NRG Therapeutics LTD (GB) 2023-07-12 — — EP disclosed
WO-2022049377-A1 NOVEL COMPOUNDS NRG THERAPEUTICS LTD (GB) 2022-03-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312466-A1 NOVEL COMPOUNDS CYP11B1, CYP11B2, UGT1A1 RXRA 1559/4885RXRB 876/4885RXRG 1055/4885
US-12497359-B2 Acrylamide derivatives ACR, GSTA2, GSTA1 RXRA 2496/4885RXRB 2705/4885RXRG 2886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback